Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells

The goal of anticancer therapy is to selectively eradicate all malignant cells. Unfortunately for the majority of patients with metastatic disease, this goal is consistently thwarted by the nearly inevitable development of therapeutic resistance; the main driver of therapeutic resistance is a minori...

Descripción completa

Detalles Bibliográficos
Autores principales: Oronsky, Bryan, Reid, Tony R., Oronsky, Arnold, Caroen, Scott, Carter, Corey A., Cabrales, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955127/
https://www.ncbi.nlm.nih.gov/pubmed/29805745
http://dx.doi.org/10.18632/oncotarget.25211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955127/
https://www.ncbi.nlm.nih.gov/pubmed/29805745
http://dx.doi.org/10.18632/oncotarget.25211

Ejemplares similares